The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers  by Cremers, Ruben G. et al.
Urologic Oncology: Seminars and Original Investigations 33 (2015) 202.e19–202.e28http://dx.doi.org/10.1016/j
1078-1439/r 2015 The A
(http://creativecommons.o
Worldwide Cancer Rese
10–0596). Dr. Cremers w
stipend (No. 92003573) o
McAulay Foundation and
Research Centre at The In
* Corresponding author
E-mail address: Bart.K
1A complete list of theOriginal articleThe role of the prostate cancer gene 3 urine test in addition to serum
prostate-speciﬁc antigen level in prostate cancer screening among breast
cancer, early-onset gene mutation carriers
Ruben G. Cremers, M.D.a, Rosalind A. Eeles, M.D., Ph.D.b,c, Elizabeth K. Bancroft, Ph.D.b,c,
Janneke Ringelberg-Borsboom, M.Sc.d, Hans F. Vasen, M.D., Ph.D.d,
Christi J. Van Asperen, M.D., Ph.D.e, The IMPACT Steering Committee1, Jack A. Schalken, Ph.D.f,
Gerald W. Verhaegh, Ph.D.f, Lambertus A. Kiemeney, Ph.D.a,*
a Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
b The Institute of Cancer Research, London, UK
c Royal Marsden Hospital NHS Foundation Trust, London, UK
d The Netherlands Foundation for the Detection of Hereditary Tumours, Leiden, the Netherlands
e Department of Clinical Genetics, Leiden University Medical Centre, Leiden, the Netherlands
f Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
Received 24 December 2014; received in revised form 22 January 2015; accepted 23 January 2015Abstract
Objective: To evaluate the additive value of the prostate cancer gene 3 (PCA3) urine test to serum prostate-speciﬁc antigen (PSA) in
prostate cancer (PC) screening among breast cancer, early-onset gene (BRCA) mutation carriers. This study was performed among the Dutch
participants of IMPACT, a large international study on the effectiveness of PSA screening among BRCA mutation carriers.
Materials and methods: Urinary PCA3 was measured in 191 BRCA1 mutation carriers, 75 BRCA2 mutation carriers, and 308
noncarriers. The physicians and participants were blinded for the results. Serum PSA level Z3.0 ng/ml was used to indicate prostate
biopsies. PCA3 was evaluated (1) as an independent indicator for prostate biopsies and (2) as an indicator for prostate biopsies among
men with an elevated PSA level. PC detected up to the 2-year screening was used as gold standard as end-of-study biopsies were not
performed.
Results: Overall, 23 PCs were diagnosed, 20 of which were in men who had an elevated PSA level in the initial screening round. (1)
PCA3, successfully determined in 552 participants, was elevated in 188 (cutoffZ25; 34%) or 134 (cutoffZ35; 24%) participants,
including 2 of the 3 PCs missed by PSA. PCA3 would have added 157 (Z25; 28%) or 109 (Z35; 20%) biopsy sessions to screening with
PSA only. (2) Elevated PCA3 as a requirement for biopsies in addition to PSA would have saved 37 (cutoffZ25) or 43 (cutoff Z35) of the
68 biopsy sessions, and 7 or 11 PCs would have been missed, respectively, including multiple high-risk PCs. So far, PCA3 performed best
among BRCA2 mutation carriers, but the numbers are still small. Because PCA3 was not used to indicate prostate biopsies, its true diagnostic
value cannot be calculated.
Conclusions: The results do not provide evidence for PCA3 as a useful additional indicator of prostate biopsies in BRCA mutation
carriers, as many participants had an elevated PCA3 in the absence of PC. This must be interpreted with caution because PCA3 was not used
to indicate biopsies. Many participants diagnosed with PC had low PCA3, making it invalid as a restrictive marker for prostate biopsies in.urolonc.2015.01.018
uthors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
rg/licenses/by-nc-nd/4.0/).
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Prostate cancer (PC) is the most frequently diagnosed
cancer in men in the Western world [1]. Serum prostate-
speciﬁc antigen (PSA) testing is the only commonly used
biomarker for PC, but its low speciﬁcity has led to a
consensus not to implement population-wide screening
[2,3]. Possibly, the advantages of screening may outweigh
the disadvantages for groups with an increased risk of PC. It
has been suggested that carriers of a pathogenic mutation in
one of the “breast cancer, early-onset” genes (BRCA1 or
BRCA2) have an increased risk of PC [4,5]. Particularly,
BRCA2 mutation carriers might present with PC at a younger
age, more aggressive disease, and shorter survival [6–10]. To
evaluate the effectiveness of PSA screening in BRCA
mutation carriers, an international study was initiated, entitled
“IMPACT: Identiﬁcation of Men with a genetic predisposi-
tion to ProstAte Cancer: Targeted screening in BRCA1/2
mutation carriers and controls” (www.impact-study.co.uk).
The results of IMPACT's ﬁrst screening round have already
been published. These preliminary results support PSA
screening among BRCA2 mutation carriers [11,12].
The large number of false-positive results on PSA tests,
particularly in the range of 3 to 10 ng/ml, has prompted
ongoing research into new (bio)markers to improve PC
diagnosis. One of the promising biomarkers, prostate cancer
gene 3 (PCA3), was discovered in 1999 as a gene that isFig. 1. The IMPACT screening protocol in the Netherlands adapted according to
intraepithelial neoplasia.strongly up-regulated in PC [13]. Based on the prostate-
speciﬁc and cancer-associated expression of PCA3, the
PROGENSA urine-based test was developed. Previous multi-
center studies suggested that its speciﬁcity and sensitivity were
signiﬁcantly higher than those of evaluation of serum PSA
levels [14–16]. PCA3 is currently used as a biomarker to
determine the need for repeat biopsies when PSA level
remains elevated after prostate biopsies with negative results.
We aimed to determine the potential role of PCA3 in addition
to PSA testing in this high-risk group by performing a
substudy among the Dutch participants of IMPACT.2. Materials and methods
Men who were eligible for IMPACT, i.e., BRCA mutation
carriers and their relatives who were proven noncarriers, were
identiﬁed and contacted by the 10 Dutch Clinical Genetic
Centres. All eligible men received an invitation by mail,
including a detailed patient information leaﬂet describing
IMPACT and the Dutch substudy (IMPACT-NL). The
IMPACT protocol has been described in detail elsewhere
[17]. Owing to restrictions set by the Dutch Minister of Health
(the Dutch “Law on Screening” requires all cancer screening
projects to obtain ministerial approval), the IMPACT-NL
protocol (Fig. 1) deviated from the IMPACT protocol: (1) the
screening interval was once every 2 years instead of annually;the ministerial approval. CGC ¼ clinical genetic center; PIN ¼ prostate
R.G. Cremers et al. / Urologic Oncology: Seminars and Original Investigations 33 (2015) 202.e19–202.e28 202.e21(2) men were eligible if they were between 45 and 69 years
instead of 40 to 69 years of age; (3) only men who were not
tested for PC before were eligible; and (4) end-of-study
biopsies were not allowed. Informed consent was sent to the
study coordinator (J.R.B.) at the Netherlands Foundation for
the Detection of Hereditary Tumours.
Of the 2,181 men who were invited, 500 refused consent
and 458 did not reply. Of the 1,223 men providing informed
consent, 552 had undergone previous PC testing (including
42 men with PC) and were excluded (Fig. 2). Of the 671
remaining men, 634 completed a baseline questionnaire and
were referred to a urologist. In IMPACT-NL, in addition to a
serum sample for PSA analysis (analyzed at the screening
site) all participants provided a urine sample after digital
rectal examination (DRE). The urine samples were collected
by the urologist at the screening site, immediately transferred
to collection and transportation tubes, and sent to Novio-
Gendix Servicelab (Nijmegen, the Netherlands). On arrival,
the samples were frozen and stored. Samples were analyzed
according to the manufacturer's protocol in regular runs
together with clinical samples, using the PROGENSA PCA3
test. The initial screening round was completed by 574
participants (191 BRCA1 mutation carriers, 75 BRCA2
mutation carriers, and 309 noncarriers). To avoid interference
with the IMPACT protocol, PCA3 scores were not used to
indicate prostate biopsies. To ensure this, both urologists and
participants were blinded toward the PCA3 scores.
Prostate biopsies were taken at the departments of urology
of the hospitals of referral, all of which adhere to the
guidelines of the Dutch Association of Urology. According
to this guideline, at least 8 transrectal prostate biopsies are
taken (the traditional “sextant biopsies” complemented with
at least one extra biopsy on each side—preferably from the
anterolateral peripheral zone). If PC was diagnosed, stagingFig. 2. Flowchart of the invitations and response raand treatment decisions were based on to the national
guidelines at the discretion of the treating urologist.
If participants had an elevated PSA level and negative
results on prostate biopsy, they were rescreened after 1 year
(repeat screening round). Men with a normal PSA level on
the initial screening were rescreened after 2 years. The results
of the repeat and the 2-year screening round were also
presented, as to enable the detection of PC up to and until the
second screening (a 2-y period) to serve as gold standard for
the diagnostic performance in the initial screening round.
The Netherlands Foundation for the Detection of Heredi-
tary Tumours collected all data regarding PSA, prostate
biopsies, PC diagnoses, staging, and initial therapy by
standardized forms completed by the treating physicians.
These data were used to stratify the PCs into low,
intermediate, and high risk using the 2014 NICE-classi-
ﬁcation, which is identical to the d'Amico risk classiﬁcation:
high-risk included all PCs with lymph node or distant
metastases and PCZpT2c, PSA level420, or Gleason
score Z8; intermediate risk included PC without high-risk
features and with pT2b, PSA 10 to 20 ng/ml, or Gleason
score of 7; low risk included PC without high risk or
intermediate-risk features [18,19]. If postsurgical TNM
staging and Gleason score were not available, clinical stage
and biopsy Gleason score were used. Data regarding carrier
status and the PCA3 scores were sent directly to the study
coordinator (J.R.B.), who coded and stored all data. The
ﬁrst author (R.C.) was provided with an anonymized
version of the database to perform the data analyses.
2.1. Statistical analysis
PCA3 was evaluated (1) as a supplementary test, indicating
prostate biopsies if either PSA level or PCA3 was increased ortes for the Dutch part of the IMPACT study.
Table 1
Baseline characteristics of the participants, stratiﬁed by BRCA mutation status
BRCA1 carriers, n ¼ 191 BRCA2 carriers, n ¼ 75 Noncarriers, n ¼ 309 Total, n ¼ 575
Age group in years, n (%)
45–49 38 (20%) 8 (11%) 44 (14%) 90 (16%)
50–59 73 (38%) 33 (44%) 139 (45%) 245 (43%)
60–69 80 (42%) 34 (45%) 126 (41%) 240 (42%)
Family history of prostate cancer
Yes 25 (13%) 13 (17%) 51 (17%) 89 (15%)
No 99 (52%) 39 (52%) 147 (48%) 285 (50%)
Unknown 66 (35%) 23 (31%) 111 (36%) 200 (35%)
BMI (median, P5–P95) 26.5 (22.2–34.7) 26.2 (21.2–33.2) 26.5 (22.2–32.3)
Comorbidity
Cardiac disease 31 (17%) 15 (20%) 42 (14%) 88 (15%)
Renal disease 6 (3%) 3 (4%) 18 (6%) 27 (5%)
History of cancer 18 (10%) 13 (17%) 15 (5%) 46 (8%)
LUTS 37 (20%) 20 (27%) 69 (22%) 126 (22%)
Prostatitis 3 (2%) 2 (3%) 3 (1%) 8 (1%)
Urinary tract infections 12 (6%) 4 (5%) 14 (5%) 30 (5%)
BMI ¼ body mass index; LUTS ¼ lower urinary tract symptoms.
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PCA3 was elevated among men with an elevated PSA levels.
Cutoff valuesZ25 andZ35 for PCA3 were evaluated and
results were stratiﬁed by BRCA mutation status. We calculated
detection rates as a percentage of diagnoses for all participants
per BRCA mutation stratum and the positive predictive value
(PPV) of the PSA test among the biopsied men per stratum.
We calculated the Spearman rho correlation between PCA3
and PSA level and made cross-tables for the concordance
between PCA3 and PSA level.3. Results
The BRCA mutation carriers and the noncarriers were
comparable with respect to age, BMI, and comorbidity. The
BRCA2 mutation carriers more often reported a medical
history of neoplasms (Table 1), particularly nonmelanoma
skin cancer (5 noncarriers, 2 BRCA1, and 2 BRCA2
mutation carriers), colorectal cancer (2 noncarriers, 4
BRCA1, and 2 BRCA2 mutation carriers) and breast cancer
(1 noncarrier and 4 BRCA2 mutation carriers).
In the initial screening round, PSA was elevated in 75
participants (Table 2). Additionally, 6 of these men also
had abnormalities on DRE. Of the participants with an
elevated PSA level, 69 underwent prostate biopsies,
including all 6 men with abnormalities on DRE. In 14 of
these men, PC was diagnosed (PPV 14/69 ¼ 20%), none
of whom had abnormalities on DRE. Of the men with a
normal PSA level, 7 had abnormalities on DRE, 4 of
whom underwent prostate biopsies. Additionally, 4 men
with a normal PSA level and a normal ﬁndings on
DRE underwent prostate biopsies. No PCs were found
among these men. The detection rate in BRCA2 mutationcarriers was 4.0% vs. 1.6% in BRCA1 carriers and 2.6% in
noncarriers.
In the repeat screening round among 52 men with an
elevated PSA level and negative ﬁndings on biopsies, 5 PCs
were diagnosed.
In the 2-year screening round, 50 men had an elevated
PSA level, including 4 with abnormalities on DRE. Of the,
25 men underwent prostate biopsies. Further, 4 PCs were
detected in 435 screened men (78% of the 556 men at risk).
One of these 4 men also had abnormalities on DRE in this
round and 3 had PSA levelo3.0 ng/ml in the initial
screening round. In the initial screening round, PSA level
was elevated for all 13 intermediate- and high-risk PCs
detected in this study (Table 3), 11 of which were detected
in the ﬁrst biopsy session. PSA performed best among
BRCA2 mutation carriers, i.e., in this group, all PCs were
detected in the initial screening round. Using the gold
standard of PC detected in the ﬁrst 2 years, the diagnostic
performance of PSA among BRCA2 carriers was as follows:
PPV ¼ 25%, sensitivity ¼ 100%, negative predictive
value (NPV) ¼ 100%, and speciﬁcity ¼ 85%. DRE
showed very poor results, with abnormalities in only 2
(1 low-risk and 1 intermediate-risk PC) of the 23 PCs.
The PCA3 score was successfully determined in 552
men (96%). The correlation between PSA level and PCA3
was 0.19 (Fig. 3). Use of PCA3 Z 25 as a supplementary
marker would result in 157 additional biopsies, more than
double the number of biopsies indicated by PSA alone
(Table 4). Among these 157 men (28%), 2 men were
diagnosed with PC during the 2-year screening round, based
on an increased PSA level. A PCA3 score Z35 would
indicate prostate biopsies for 109 (20%) additional men,
including the same 2 men with PC diagnosed after 2 years.
The results for PCA3 Z 35 were best for the BRCA2
Table 2
Breakdown of serum PSA values and screening strategies at different time points, stratiﬁed by BRCA mutation status
BRCA1 carriers BRCA2 carriers Noncarriers Total
Initial screening
Participants with valid serum PSA level (n) 191 75 308 574
Serum PSAZ3.0 ng/ml 19 (10%) 12 (16%) 44 (14%) 75 (13%)
Abnormalities on DRE 5 (3%) 3 (4%) 5 (2%) 13 (2%)
Prostate biopsies 18 (9%) 12 (16%) 47 (15%) 77 (13%)
Prostate cancer 3 (1.6%) 3 (4.0%) 8 (2.6%) 14 (2.4%)
1-year repeat screening (only for men with a known elevated PSA)
Participants with valid serum PSA level (n) 17 7 28 52a
Serum PSA levelZ3.0 ng/ml 14 (82%) 2 (29%) 19 (68%) 35 (67%)
Abnormalities on DRE 1 (6%) 0 1 (4%) 3 (6%)
Prostate biopsies 7 (41%) 0 15 (54%) 22 (42%)
Prostate cancer 2 (12%) 0 3 (11%) 5 (10%)
2-year screening
Participants with valid serum PSA (n) 148 (out of 186) 62 (out of 72) 225 (out of 298) 435a (out of 556)
Serum PSAZ3.0 ng/ml 18 (12%) 3 (5%) 29 (13%) 50 (12%)
Abnormalities on DRE 2 (1%) 0 6 (3%) 8 (2%)
Prostate biopsies 9 (6%) 2 (3%) 17 (8%) 28 (6%)
Prostate cancer 1 (0.7%) 0 3 (1.3%) 4 (0.9%)
aReported reasons for nonparticipation in the subsequent screening rounds were mainly: personal reasons (n ¼ 19), health insurance issues (n ¼ 28), other
illness (n ¼ 11), second-year screening still to be performed (n ¼ 17), and second-year screening results still to be received (n ¼ 20).
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indicated by high PCA3; NPV ¼ 98%), although the
absolute numbers were small.
Use of PCA3 to withhold biopsies in men with an
elevated PSA level would have reduced the number of
biopsies in the initial screening round by more than half
from 68 to 31 (Table 4). A PCA3 cutoff Z35 would have
decreased this further to 25 biopsy sessions. This would
come at the cost of missing, respectively, 7 and 11 PCs of
the 22 PCs in this substudy. Among these, multiple
intermediate- and high-risk PCs would have been present.4. Discussion
This study did not ﬁnd a clear role for PCA3 in addition
to PSA screening among BRCA mutation carriers. Use of
PCA3 as a supplementary indicator of prostate biopsies
seemed to result in a relatively large number of additional
prostate biopsies to identify only a few PCs. However, in
the absence of end-of-study biopsies, it is impossible to
estimate the real PPV of PCA3 at this point. We can
conclude that a restrictive use of PCA3, i.e., to diminish the
number of biopsies among men with an elevated PSA level,
is not a good strategy in this study population. Too many
intermediate- and high-risk PCs would be missed, if
prostate biopsies were to be withheld based on the
PCA3 score.
PSA level in the initial screening round showed good
results, appearing to miss only 3 PCs that were detected in
the 2-year follow-up (FU), although not all PCs were found
in the ﬁrst biopsy session. All PCs that were detected duringthe 2-year screening round were low-risk PCs that revealed
themselves by an increased PSA level during the 2-year
screening round. These results might be an overestimation,
as no end-of-study biopsies were performed. One may
argue that end-of-study biopsies would give a more reliable
estimate of the NPV of PSA than our somewhat arbitrary
gold standard of PC detected in the ﬁrst 2 years in this
study. The counter argument is that end-of-study biopsies
lead to a considerable overdiagnosis of PC, as was shown in
the PCPT trial [20]. A better alternative for end-of-study
biopsies is a much longer FU period to see which men will
be diagnosed with PC. Another comment to the current
screening strategy could be that, even though it does not
seem likely that many high-risk PCs were missed, the
BRCA2 mutation carriers might require an even more
stringent PSA cutoff, as discussed by Bancroft et al. [12].
In the absence of end-of-study biopsies or a longer FU
period, we can only speculate about whether a different
PSA cutoff should be used in BRCA2 mutation carriers.
Unfortunately, a limitation of the study is that the ﬁnancial
resources prohibited more screening rounds. For example,
for a good evaluation of the risk of interval cancers,
complete FU until the third screening round is necessary.
The results for PCA3 seem modest. For comparison
purposes, the most important study is by Roobol et al. [21],
which is to our knowledge the only study that used PCA3
(cutoff Z10) as a supplementary indicator for prostate
biopsies. Their biopsy protocol (biopsy indicated for either
PSA level Z3.0 ng/ml or PCA3 Z 10) resulted in 721 of
the 965 men (75%) being biopsied. In these biopsy sessions,
122 PCs were diagnosed, only 19 of which were classiﬁed
as “serious” PCs (deﬁned as stage ZcT2a or any Gleason
Table 3
Clinical and diagnostic characteristics of the Dutch patients with prostate cancer detected in different screening rounds, including family members diagnosed with PC before IMPACT
Patient Detection Mutation status Age, y Disease risk classiﬁcationa PSA level, ng/mlb Abnormal DREb PCA3 scoreb Gleason scoreb pTNM/cTNM Primary treatment
1 Initial screening Noncarrier 61 High 4.80 N 469 3 þ 3 ¼ 6 pT2cNxMxR0 RALP
2 Initial screening Noncarrier 62 High 4.80 N 21 3 þ 3 ¼ 6 pT2cN0R0 RRP
3 Initial screening Noncarrier 53 High 3.40 N 25 3 þ 3 ¼ 6 pT2cNxMxR0 RALP
4 Initial screening Noncarrier 62 High 3.28 N 23 3 þ 3 ¼ 6 pT2c RALP
5 Initial screening Noncarrier 65 High 4.70 N 30 3 þ 3 ¼ 6 pT2cN0M0 RALP
6 Initial screening BRCA1 mutation 64 Low 6.20 N 13 3 þ 3 ¼ 6 cT1c Active surveillance
7 Initial screening BRCA1 mutation 57 High 3.70 N 27 3 þ 3 ¼ 6 pT2cNxMxR0 RRP
8 Initial screening BRCA2 mutation 61 Low 3.60 N 38 3 þ 3 ¼ 6 cT1c Brachytherapy
9 Initial screening Noncarrier 62 High 9.90 N – 3 þ 3 ¼ 6 pT2cN0MxR0 RALP
10 Initial screening Noncarrier 60 Low 5.50 N 27 3 þ 3 ¼ 6 cT1c Active surveillance
11 Initial screening BRCA2 mutation 55 High 4.50 N 14 4 þ 3 ¼ 7 pT3b RRP
12 Initial screening Non-carrier 57 High 4.50 N 17 3 þ 4 ¼ 7 pT2c RALP
13 Initial screening BRCA2 mutation 61 High 6.30 N 61 8 pT2b RRP
14 Initial screening BRCA1 mutation 61 Intermediate 9.70 N 22 4 þ 3 ¼ 7 pT2aR0 RRP
15 Repeat screening Noncarrier 67 Low 4.40/2.50 N/N 40 NM/3 þ 3 ¼ 6 cT2NxM0 Active surveillance
16 Repeat screening Noncarrier 62 Intermediate 3.70/ N/N 144 NM/3 þ 4 ¼ 7 pT2aN0M0 RALP
17 Repeat screening BRCA1 mutation 67 Low 6.49/5.30 N/Y 56 NM/3 þ 3 ¼ 6 – –
18 Repeat screening BRCA1 mutation 59 Low 9.00/4.40 N/N 103 NM/3 þ 3 ¼ 6 cT1cNxMx Active surveillance
19 Repeat screening Noncarrier 62 Low 4.20/11.0 N/N 16 NM/3 þ 3 ¼ 6 cT1a –
20 Two-year screening BRCA1 mutation 57 Low 2.60/4.40 N/N 35/441 3 þ 3 ¼ 6 cT1c Active surveillance
21 Two-year screening Noncarrier 60 Low 2.50/3.10 N/N 44/32 3 þ 3 ¼ 6 cT1cNxMx Active surveillance
22 Two-year screening Noncarrier 53 Low 2.30/3.20 N/N o16/8 3 þ 3 ¼ 6 cT1c Active surveillance
23 Two-year screening Noncarrier 59 Intermediate 9.2/11.0/14.9 N/N/Y 47/ NM/NM/3 þ 3 ¼ 6 cT1a –
x1 Before IMPACT Noncarrier 50 Low 5.10 – – 5 pT2aNxMx RRP
x2 Before IMPACT Noncarrier 59 High 5.40 – – 8 pT2cNxM0 Laparoscopic/RALP
x3 Before IMPACT Unknown 65 High – – – 6 pT3aNxM0 RRP
x4 Before IMPACT BRCA1 mutation 61 High 7.90 – – 7 cT2cNxM0 TURP þ thermo-ablation
x5 Before IMPACT BRCA2 mutation 56 High 6.00 – – 7 pT2cNxMx RRP
x6 Before IMPACT Noncarrier 56 High – – – 7 pT2cNxMx RRP
x7 Before IMPACT BRCA1 mutation 58 High 6.20 – – 6 pT2cNxM0 RRP
x8 Before IMPACT BRCA1 mutation 65 High 4.40 – – 7 pT2cNx Laparoscopic/RALP
x9 Before IMPACT BRCA2 mutation 61 High 12.3 – – 9 cT1cN0M0 EBRT
x10 Before IMPACT BRCA1 mutation 59 Low – – – 6 pT2NxMx RRP
x11 Before IMPACT BRCA2 mutation 52 High 130 – – 9 cT2NxM1B HT (surgical)
x12 Before IMPACT BRCA2 mutation 63 Low 2.10 – – 6 pT2aNx Laparoscopic / RALP
x13 Before IMPACT Unknown 47 High – – – 9 cT3N1M1 HT (medicinal)
x14 Before IMPACT Noncarrier 65 High – – – 6 pT2cNxMx RRP
x15 Before IMPACT Noncarrier 59 High 7.70 – – – pT3aN0M0 RRP
x16 Before IMPACT BRCA2 mutation 64 High 40.0 – – 7 cT1cN1M0 HT (medicinal)
x17 Before IMPACT Unknown 65 High – – – 9 cT2cN1M0 HT (medicinal)
x18 Before IMPACT BRCA1 mutation 59 Intermediate 16.3 – – – cT2bN0M0 EBRT þ HT (medicinal)
x19 Before IMPACT BRCA1 mutation 59 Low 6.3 – – 6 pT2aNxM0 laparoscopic / RALP
x20 Before IMPACT BRCA2 mutation 59 High 25.6 – – 6 cT3aN0M1 HT (medicinal)
x21 Before IMPACT BRCA2 mutation 50 High – – – 6 pT2cNxMx RRP
x22 Before IMPACT BRCA1 mutation 59 Low 8.30 – – 6 cT1cNxM0 active surveillance
R
.G
.
C
rem
ers
et
al.
/
U
rologic
O
ncology:
Sem
inars
and
O
riginal
Investigations
33
(2015)
202.e19
–202.e28
202.e24
x23 Before IMPACT Noncarrier 54 Low 3.70 – – – pT2aNxMx RRP
x24 Before IMPACT Unknown 63 Low – – – – cT1cN0Mx active surveillance
x25 Before IMPACT BRCA2 mutation 62 High 96.0 – – 7 cT3aN1M0 EBRT þ HT (medicinal)
x26 Before IMPACT Non-carrier 60 High 18,1 – – 6 cT2cN0M0 EBRT
x27 Before IMPACT BRCA2 mutation 57 High 20.1 – – 7 pT2cN0M0 RRP
x28 Before IMPACT Unknown 62 High 8.60 – – 7 pT2cNxM0 laparoscopic/RALP
x29 Before IMPACT BRCA2 mutation 68 Intermediate 4.43 – – 7 cT1cNxM0 active surveillance
x30 Before IMPACT BRCA2 mutation 51 High 29.5 – – 6 cT3aN0M0 EBRT þ HT (medicinal)
x31 Before IMPACT BRCA2 mutation 63 High 7.20 – – 8 cT3aN1M0 HT (medicinal)
x32 Before IMPACT BRCA1 mutation 61 High 37.80 – – 7 cT3aN1M0 HT (medicinal)
x33 Before IMPACT BRCA2 mutation 64 Intermediate 4.40 – – 6 pT2bNxMx RRP
x34 Before IMPACT Noncarrier 60 Low 7.30 – – 6 cT1cNxM0 Brachytherapy
x35 Before IMPACT BRCA1 mutation 66 High 8.40 – – 6 pT2cN0M0 RRP
x36 Before IMPACT BRCA2 mutation 62 High 15.3 – – 6 pT3aNxM0 RRP
x37 Before IMPACT Non-carrier 58 Low – – – – cT2aNxM0 EBRT
x38 Before IMPACT Non-carrier 57 High 6.40 – – 6 pT2cN0M0 Laparoscopic/RALP
x39 Before IMPACT BRCA2 mutation 63 Low 6.00 – – 6 pT2NxMx RRP
x40 Before IMPACT BRCA2 mutation 68 Low – – – 6 cT1cNxM0 Active surveillance
x41 Before IMPACT BRCA1 mutation 63 Low – – – 5 cT1aNxMx TURP
x42 Before IMPACT Noncarrier 54 High 134 – – 7 pT3bN0M0 EBRT þ HT (medicinal)
EBRT ¼ external beam radiation therapy; HT ¼ hormonal therapy; NM ¼ no malignancy (on prostate biopsy); RALP ¼ robot-assisted laparoscopic prostatectomy; RRP ¼ radical retropubic
prostatectomy; pTNM/cTNM ¼ tumor-node-metastasis staging system (postsurgical pathological vs. clinical stage); TURP ¼ transurethral resection of the prostate.
aRisk stratiﬁcation was performed according to the 2014 NICE guidelines: high-risk PC: any PC with pTZ T2c, pNþ, pMþ, PSA level4 20 ng/ml, or Gleason score Z8; intermediate risk: any PC pT2b,
PSA level ¼ 10–20 ng/ml, or Gleason score ¼ 7; low-risk: all PCs with pT1-pT2a, PSA levelo10 ng/ml, or Gleason score 6. If pathological TNM staging and Gleason score were not available, clinical stage
and biopsy Gleason score were used.
bFor men with PC detected after the initial screening round, outcomes of the tests, as well as the outcomes of previous prostate biopsy sessions are denoted in consecutive order.
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Fig. 3. Correlation (Spearman ρ ¼ 0.19) between serum PSA level and urinary PCA3 in 552 participants with a valid PCA3 score, stratiﬁed by BRCA
mutation status.
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according to the NICE deﬁnition) [18]. If they had used the
higher cutoff, as described in our substudy, to indicate
prostate biopsies (PCA3Z 35), this would still have
resulted in biopsies in far too many men in their study
(48% of their participants had a PCA3Z 35 as compared
with 24% in our study). The authors reported a higher PPV
for PCA3 Z 35 (24%) when looking at all PCs. However,
only 16% of the detected PCs were intermediate- or high-
risk PCs. The Roobol study was different from ours in
several ways: the participants were on an average older and
had all undergone multiple previous screening sessions. The
most important difference is that PCA3 was used to indicate
prostate biopsies. When comparing the PPV in our studyTable 4
Concordance between PSA level and PCA3 at the initial screening and cancer d
BRCA1 carriers BRCA2 car
PSA level in the initial screening round
Participants with valid PCA3 score (n) 181
PCA3Z25 PCA3o25 PCA3Z25
PSA levelZ3.0 ng/ml 7 (3 PC) 10 (2 PC) 6 (2 PC)
PSA levelo3.0 ng/mlb 60 (1 PC) 104 (0 PC) 14 (0 PC)
PCA3Z35 PCA3o35 PCA3Z35
PSA levelZ3.0 ng/ml 5 (2 PC) 12 (3 PC) 6 (2 PC)
PSA levelo3.0 ng/ml 41 (1 PC) 123 (0 PC) 9 (0 PC)
aNote that one of the men with PC (Table 2, patient 9) did not have a valid P
bOnly men with PSA levelZ3.0 ng/ml underwent prostate biopsies. The 3 P
2-year screening round; these participants underwent prostate biopsies because of
and the 2-year screening round. Of the PCs detected in men with a PSA levelZ
negative biopsy results in the previous screening round.with yet other studies, the results in our study are still rather
modest [15,22,23]. However, as discussed before, we
cannot give a deﬁnitive statement about the PPV of PCA3
as the FU period is still too short. With respect to the NPV
of PCA3, the performance was also modest than the other
studies. A relatively large number of intermediate- and
high-risk PCs would have been missed at PCA3 cutoff
values that have performed signiﬁcantly better in previous
studies. A possible explanation for this could be that PC in
BRCA families might have a different etiological pathway
not involving (early) increased PCA3 expression. However,
as no study investigated this hypothesis, we can only guess
the correct explanation for the relatively modest
performance.etection, stratiﬁed by BRCA mutation status
riers Noncarriers Total
73 298 552a
PCA3o25 PCA3Z25 PCA3o25 PCA3Z25 PCA3o25
5 (1 PC) 18 (7 PC) 22 (4 PC) 31 (12 PC) 37 (7 PC)
48 (0 PC) 83 (1 PC) 175 (1 PC) 157 (2 PC) 327 (1 PC)
PCA3o35 PCA3Z35 PCA3o35 PCA3Z35 PCA3o35
5 (1 PC) 14 (4 PC) 26 (7 PC) 25 (8 PC) 43 (11 PC)
53 (0 PC) 59 (1 PC) 199 (1 PC) 109 (2 PC) 375 (1 PC)
CA3 score.
Cs in men with an initial PSA levelo3.0 ng/ml were detected during the
a PSA level that had increased toZ3.0 ng/ml in the time between the initial
3.0 ng/ml, 6 were detected in the repeat and second screening rounds after
R.G. Cremers et al. / Urologic Oncology: Seminars and Original Investigations 33 (2015) 202.e19–202.e28 202.e27In our substudy, the BRCA2 mutation carriers had an
increased prevalence of PC in the ﬁrst screening round. This
difference diminished, as PCs in the consecutive screening
rounds were only detected among BRCA1 mutation carriers
and noncarriers. The suggested association between BRCA
mutations, particularly BRCA2 mutations, and PC risk is
more supported by the number of PCs detected before the
study (Table 3). This may be the reﬂection of the
genetically increased risk of PC that men with a BRCA
mutation have been reported to have. An alternative
explanation is ascertainment bias. It is imaginable that
particularly men with a known BRCA mutation were more
intensively screened for PC before IMPACT than non-
carriers, as a relationship between BRCA mutations and PC
has been reported for quite some time. Either way, assum-
ing that a causal relationship exists between a germline
BRCA mutation and PC, the exclusion of these family
members from this study cannot affect the results among
screening-naïve participants [24].
The highest PPV for PSA level was found for BRCA2
mutation carriers, suggesting that this might be the most
interesting group for further research. PCA3 also performed
best among BRCA2 mutation carriers. However, the abso-
lute numbers (3 PCs were detected among 75 BRCA2
mutation carriers) are small, warranting caution when
drawing any conclusions.5. Conclusions
PCA3 should not be used as a restrictive marker next to
PSA level for PC screening in BRCA mutation carriers.
PCA3 did not show sufﬁcient additive value to be imple-
mented as a supplementary indicator of prostate biopsies
next to PSA level, although in the absence of prostate
biopsies based on PCA3, its true diagnostic performance
cannot be calculated. A longer FU period is needed to show
whether PCA3 will be a valuable addition to any PC
screening protocol.
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